Nightingale Health announces opening of its Singapore laboratory
Nightingale Health Plc
Press release
29 November 2024 at 11:30 a.m. (EET)
Nightingale Health, a pioneer in disease risk detection and preventative health announces the opening of its Singapore laboratory: the opening ceremony that will be held on Monday 2nd December 2024 marks an important milestone in Nightingale Health’s global expansion. Located in the hub of Southeast Asia, the laboratory is now ready to serve healthcare and medical research customers in the region.
Nightingale Health announced earlier this month that it has the regulatory readiness to start providing its blood analysis service in Singapore. In parallel with the regulatory processes, Nightingale Health has been setting up the laboratory and data processing readiness, and that work has now successfully been accomplished. After opening the laboratory, the main focus of the project will be shifted towards commercial activities.
“With the laboratory set up completed, we can now focus on our sales activities at full speed together with our partner Innoquest Diagnostics and we are expecting the first healthcare samples to the lab in the first quarter of 2025” says Satu Saksman, Nightingale Health's COO and Co-founder, who leads the operations in Singapore. “We’d like to welcome our partners, customers and other stakeholders to celebrate this achievement, which is the result of hard work from multiple teams both within Nightingale Health and Innoquest Diagnostics.” Saksman continues.
For further information, please contact:
Teemu Suna, CEO
ir@nightingalehealth.com
About Nightingale Health
Nightingale Health’s mission is to build sustainable healthcare and reduce health inequalities. Nightingale Health has developed the world’s most advanced health check that provides risk detection for multiple chronic diseases from a single blood sample. Nightingale’s Health Check can be scaled to entire populations at a low cost, and it can replace many of the current clinical risk assessments. Detecting disease risks on a population level allows for the effective targeting and tracking of health interventions, and better prevention of the onset of chronic diseases. With every sample we help to create a healthier world.
Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com/
Tags:
